1.Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma
Michael XIANG ; Elizabeth A. KIDD
Journal of Gynecologic Oncology 2020;31(4):e39-
Objective:
To better delineate optimal management of high-risk, early-stage endometrial cancer, as national guidelines permit substantial practice variations.
Methods:
Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB grade 3 and stage II endometrioid carcinoma who underwent at least total hysterectomy were identified in SEER-Medicare. Adjuvant treatments were brachytherapy (BT), external beam radiation therapy (EBRT), and chemotherapy. Death from endometrial cancer (cancerspecific mortality [CSM]) and local recurrence were analyzed using Gray's test and FineGray regression.
Results:
In total, 1,095 patients were identified: 52% received BT, 56% received EBRT, 16% received chemotherapy, and 29% received no adjuvant treatment. Survival outcomes were significantly worse for stage IB grade 3 and stage II grade 3 relative to stage II grades 1–2 (5-year CSM: 18% and 23% vs. 10%; p<0.001 and p=0.003, respectively), while there was no difference between stage IB grade 3 and stage II grade 3 (p=0.618). BT had a local control benefit across all patients (p<0.001) that translated into a survival benefit in stage IB grade 3 (adjusted hazard ratio [HR] for CSM=0.47, p=0.003). EBRT had a survival benefit in stage II grade 3 (adjusted HR for CSM=0.36; p=0.031), as did lymph node dissection (p=0.015).Chemotherapy was not significantly correlated with CSM.
Conclusions
High-risk, early-stage endometrioid carcinoma is a heterogeneous population.BT was associated with a survival benefit in stage IB grade 3, whereas regional treatment with EBRT and lymphadenectomy was associated with a survival benefit in stage II grade 3.
2.Recurrence risk factors in stage IA grade 1 endometrial cancer
Chika NWACHUKWU ; Mana BASKOVIC ; Rie Von EYBEN ; Dylann FUJIMOTO ; Stephanie GIARETTA ; Diana ENGLISH ; Elizabeth KIDD
Journal of Gynecologic Oncology 2021;32(2):e22-
Objectives:
Patients with early-stage endometrial cancers (EC) with disease recurrences have worse survival outcomes. The purpose of this study was to identify clinical and pathologic factors that predict for all recurrences in stage IA grade 1 (IAG1) EC.
Methods:
Records from patients diagnosed with EC were retrospectively reviewed. Baseline characteristics of 222 patients with IAG1 EC who underwent surgical resection were analyzed.Cox proportional hazard analysis was used to identify univariate and multivariate risk factors that predict for recurrence.
Results:
Seventeen (7.65%) patients had recurrences. The 3-year cumulative incidence of recurrence were significantly higher for patients with time from biopsy to surgery ≥6 months (54% vs. 8%, p=0.003), simple hysterectomy with ovarian preservation vs. total hysterectomy and bilateral salpingo-oophorectomy (31% vs. 9%, p=0.032), any myometrial invasion vs. no invasion (18% vs. 2%, p=0.004), and tumor size ≥2 cm (15% vs. 2%, p=0.021). On, multivariate analysis, any myometrial invasion, increasing time from biopsy to surgery, and larger tumor size were independent predictors of any recurrence. Patients with recurrences had worse outcomes than those without (5-year overall survival [OS]=60%; 95% confidence interval [CI]=16%–86% vs. 5-year OS=95%; 95% CI=87%–99%, respectively, p=0.003).
Conclusion
Time from biopsy to surgery, larger tumors, and myometrial invasion are the most important predictors of recurrence. Though the recurrence rates are generally low in IAG1 EC, the survival rate for the patients with recurrences was worse than those without.Identification of additional recurrence risk factors can help select patients who may benefit from adjuvant treatment.